Nature Reviews Cancer contents January 2013 Volume 13 Number 1 pp 1-74

TABLE OF CONTENTS
January 2013 Volume 13 Number 1
Impact Factor 37.545 *	In this issue Editorial Research Highlights Reviews Also this month Calendar: Nature Reviews Cancer Calendar 2013  Featured article: WNT signalling pathways as therapeutic targets in cancer Jamie N. Anastas & Randall T. Moon
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
We've got something to share with you Access the latest scientific news and research when and where you want it. Download the latest issues to browse at your convenience, zoom in on figures and images, save your searches and synchronize your bookmarks across devices. Tap in to find out more
EDITORIAL		Top
Thoughts for a new year p1 | doi:10.1038/nrc3433 As we begin 2013 it's time to take stock of what we do know and what we don't, and consider how best to approach finding new treatments for cancer. Do we embrace complexity or go back to basics? Abstract | Full Text | PDF
RESEARCH HIGHLIGHTS Top Metastasis: Epithelial to mesenchymal and back again p3 | doi:10.1038/nrc3428 Two papers provide in vivo evidence for plasticity of epithelial and mesenchymal transitions, showing that EMT reversion is required for metastatic outgrowth. PDF Signalling: YAP, PTEN and miR-29 size each other up p4 | doi:10.1038/nrc3422 The activation of YAP is linked to the PI3K-mTOR regulation of cell size (growth) through the regulation of PTEN by the miR-29 family of microRNAs. PDF Angiogenesis: A happy medium? p4 | doi:10.1038/nrc3426 A new study shows how angiogenesis may be controlled by epsin proteins, the targeting of which can result in a tumour-suppressive form of angiogenesis. PDF IN THE NEWS Doubling up? p4 | doi:10.1038/nrc3429 A study reports the benefits of 10 years of adjuvant tamoxifen therapy for ER-positive breast cancer. PDF Signalling: Double trouble p6 | doi:10.1038/nrc3421 Phospholipase D1 signalling may promote both tumour angiogenesis and metastasis through integrin-dependent pathways. PDF Drug resistance: Time for mediation? p6 | doi:10.1038/nrc3423 The loss of a component of the transcriptional mediator complex MED12 is implicated in resistance to a number of targeted and standard chemotherapeutic agents. PDF Glioblastoma: Microvesicles as major biomarkers? p8 | doi:10.1038/nrc3424 A sensitive method to detect and monitor glioblastomas through the analysis of microvesicles in the blood is reported in Nature Medicine. PDF Colorectal cancer: A powerful model p8 | doi:10.1038/nrc3427 Using the Drosophila melanogaster midgut as a model of intestinal hyperproliferation, Julia Cordero, Owen Sansom and colleagues have identified non-cell-autonomous crosstalk among WNT-MYC, EGFR and JAK-STAT signalling pathways downstream of APC loss; importantly, this pathway may also operate in human colorectal tumours. PDF TRIAL WATCH What's a girl to do? p9 | doi:10.1038/nrc3425 PDF IN BRIEF Pancreatic cancer: Tracing origins | Metabolism: Nuclear functions | Immunology: A downside of chemotherapy | Cancer stem cells: Upping the stemness during tumour progression | Metabolism: Transporting drugs | Signalling: Modifying responses | Chromosome instability: A different kind of chromosome instability | Breast cancer: Profiling the profilins | Colorectal cancer: YAP limits expansion | Microenvironment: CAFs and miRNAs | Genomic instability: A U-turn for mutagenesis? PDF Cancer JOBS of the week Postdoctoral Fellow in Cancer Biology Georgia Health Sciences University Cancer Center Postdoctoral studies in B cell lymphoma / cancer genetics Karolinska Institutet (KI) Computational Cancer Biology Position Netherlands Cancer Institute Professor and Chair, Cancer Biology University of Cincinnati Faculty Positions in Cancer Inflammation and Tolerance Georgia Health Sciences University Cancer Center More Science jobs from Cancer EVENT 1st Symposium of the Cancer Research Center of Lyon 13.-15.02.13 Lyon, France More science events from
REVIEWS		Top
WNT signalling pathways as therapeutic targets in cancer Jamie N. Anastas & Randall T. Moon p11 | doi:10.1038/nrc3419 This Review highlights the complexity and context-dependent roles of both β-catenin-dependent and β-catenin-independent WNT signalling pathways in cancer, as well as some of the ways in which WNT signalling might be targeted therapeutically. Abstract | Full Text | PDF | Supplementary information
Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond Genevieve Deblois & Vincent Giguere p27 | doi:10.1038/nrc3396 Oestrogen-related receptors (ERRs) have been shown to control vast gene networks that are involved in glycolysis, glutaminolysis, oxidative phosphorylation, nutrient sensing and biosynthesis pathways. This Review discusses these findings in the context of breast cancer and discusses whether targeting the ERRs for the development of cancer therapeutics is feasible. Abstract | Full Text | PDF
Protein arginine methyltransferases and cancer Yanzhong Yang & Mark T. Bedford p37 | doi:10.1038/nrc3409 Protein arginine methylation has various effects on cell signalling — targeting signalling proteins as well as histones — and the protein arginine methyltransferases (PRMTs) are altered in various types of cancer, as discussed in this Review. Abstract | Full Text | PDF
Ceramide-orchestrated signalling in cancer cells Samy A. F. Morad & Myles C. Cabot p51 | doi:10.1038/nrc3398 Ceramide induces apoptosis, autophagy and cell cycle arrest and it is therefore often metabolized in tumour cells to suppress its function and promote proliferation. As also discussed in this Review, there are efforts to increase ceramide levels as a therapeutic avenue. Abstract | Full Text | PDF | Supplementary information
Identifying people at a high risk of developing pancreatic cancer Alison P. Klein p66 | doi:10.1038/nrc3420 Pancreatic cancer has the poorest prognosis of any major cancer type. Familial pancreatic cancer registries are important for investigating the genetic aetiology of this devastating disease and provide a unique opportunity for laboratory, population and clinical research. Abstract | Full Text | PDF
Advertisement
SUBSCRIBE to Nature Reviews Cancer TODAY and receive your own personal copy delivered directly to your door each month. PLUS you will gain full online access to the entire archive since launch. Nature Reviews Cancer is the no. 1 monthly review journal in oncology*. Ensure you have access.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.